Luís Masmiquel

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Bo Åhrén, Luís Masmiquel, Harish Kumar et al. · The Lancet Diabetes & Endocrinology · 2017 · 476 citations

Medicine, Pharmacology, Pharmacotherapy +15

Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial

Pilar Sanchís, Rosmeri Rivera, Francisco Berga et al. · Scientific Reports · 2018 · 65 citations · Full text

Medicine, Biochemistry, Nutritional Sciences +15

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

Luís Masmiquel, Lawrence A. Leiter, Josép Vidal et al. · Cardiovascular Diabetology · 2016 · 57 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17